Table 2.

Baseline data obtained before the first trial of the pharmacology study.

	P15
	CHOW	PF	ETOH	CHOW	PF	ETOH	CHOW	PF	ETOH
M/F (n)	4/3	6/1	4/2	5/2	4/5	2/4	4/3	3/4	3/5
wt, g	33.5 ± 0.8	35.0 ± 0.6	32.9 ± 0.8*
	aCSF			NIP			Gabazine
fH, bpm	408 ± 18	419 ± 11	440 ± 17	436 ± 18	432 ± 10	439 ± 16	440 ± 14	394 ± 17	442 ± 15
fR, breaths/min	118 ± 9	114 ± 6	124 ± 3	143 ± 8#	132 ± 5	132 ± 5	119 ± 10	124 ± 9	119 ± 3
TB, °C	33.1 ± 0.3	33.1 ± 0.4	33.0 ± 0.6	34.1 ± 0.4	33.4 ± 0.3	33.9 ± 0.4	33.9 ± 0.2	33.6 ± 0.7	34.4 ± 0.4
	CONTROL			CONTROL			CONTROL
wt, g	34.3 ± 0.5
fH, bpm	414 ± 10			434 ± 9			417 ± 12
fR, breaths/min	116 ± 5$$			137 ± 4			121 ± 6
TB, °C	33.1 ± 0.3			33.7 ± 0.2			33.8 ± 0.4

	P21
	CHOW	PF	ETOH	CHOW	PF	ETOH	CHOW	PF	ETOH
M/F (n)	3/3	2/4	2/5	5/1	2/4	3/3	4/3	2/3	3/3
wt, g	52.2 ± 1.2*	57.5 ± 2.1	52.0 ± 1.2*
	aCSF			NIP			Gabazine
fH, bpm	428 ± 21	421 ± 17	445 ± 17	419 ± 17	432 ± 25	436 ± 14	463 ± 7	480 ± 10	459 ± 11
fR, breaths/min	115 ± 9	123 ± 6	121 ± 4	140 ± 12	135 ± 6	118 ± 7$	147 ± 11##	131 ± 6.8	127 ± 5.6
TB, °C	33.7 ± 0.8	33.4 ± 2.0	35.3 ± 0.5	34.0 ± 0.7*	31.1 ± 2.3	34.8 ± 0.5$, **	33.7 ± 0.7	33.5 ± 0.4	34.5 ± 0.5
	CONTROL			CONTROL			CONTROL
wt, g	54.7 ± 1.2
fH, bpm	425 ± 13			425 ± 14			470 ± 6&,$
fR, breaths/min	118 ± 5			138 ± 7			141 ± 7&
TB, °C	33.6 ± 1.0			32.5 ± 1.2			33.7 ± 0.4

The weight (wt) was measured at P15 and P21 for all CHOW, PF, ETOH and CONTROL pups independent of injections: ^* different from PF (P < 0.05). All three diets and the CONTROL group are compared for f_H, f_R and T_B:

^*different from PF NIP (^*P < 0.05, ^**P < 0.01)

^#different from CHOW aCSF (^#P < 0.05, ^##P < 0.01);

^$different from CONTROL NIP (^$P < 0.05, ^$$P < 0.01) and

^&different from CONTROL aCSF (^&P < 0.05).

M/F, male/female

wt, weight

f_H, heart rate

f_R, respiratory rate

T_B, body temperature.

All values are mean (SEM).